About CrossBridge Bio
CrossBridge Bio is a Healthcare company based in Houston (United States) founded in 2023, and was acquired by Lilly in April 2026. Antibody-Drug Conjugate therapeutics are developed using stable dual-linker technology. CrossBridge Bio has raised $10 million across 1 funding round from investors including Lilly, TMC Venture Fund and CE Ventures. CrossBridge Bio offers products and services including ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
CrossBridge Bio was founded in 2023 and is headquartered in Houston, United States. Antibody-Drug Conjugate therapeutics are developed within the biotechnology sector, with operations centered on a stable dual-linker payload technology. This technology supports various candidates, including the lead CB-120, which targets cancer treatment. Focus is placed on oncology applications through research and therapeutic development.
- Headquarters Houston, United States
- Stage Acquired
- SectorsHealthcare
- Website crossbridgebio.com
- Social LinkedIn X
- Acquired by Lilly (Apr 2026)
Products & Services of CrossBridge Bio
CrossBridge Bio offers a comprehensive portfolio of products and services, including ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation.
Platform for creating stable Antibody-Drug Conjugates to target cancer cells effectively.
Enzymatically cleavable linker enhancing ADC stability and targeted payload release.
Technique for precise integration of multi-arm linkers in ADC production.
Funding Insights of CrossBridge Bio
CrossBridge Bio has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Seed round of $10 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 1
- Last Round Seed — $10M
- First Round $10M
(Nov 2024)
- Investors Count 6
All 1 funding rounds of CrossBridge Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $10M | Seed | – | TMC Venture Fund, CE Ventures |
7 investors in total: 7 institutional.
Investors in CrossBridge Bio
CrossBridge Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, TMC Venture Fund and CE Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage Life-Sciences & Offline focused VC firm funding companies in the US | tmcventurefund.com | Houston, United States | ||
Stage-agnostic tech-focused VC firm investing in geographies such as Israel and China | ceiif.com | |||
Portal Innovations is engaged in funding life sciences startups. | portalinnovations.com | Chicago, United States | ||
Services across port management, logistics, aviation and procurement and construction industry | crescententerprises.com | Sharjah, United Arab Emirates | ||
| lindenlakelabs.com | ||||
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States |
Investor details for CrossBridge Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CrossBridge Bio
3 dated milestones of CrossBridge Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded CrossBridge Bio is founded.
- Funding First funding round of $10.0M.
- Exit Acquired by Lilly.
Competitors of CrossBridge Bio
CrossBridge Bio has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of CrossBridge Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CrossBridge Bio
The website of CrossBridge Bio (crossbridgebio.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 21.2% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as CrossBridge Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Crossbridge Bio
Complete news archive for CrossBridge Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CrossBridge Bio
CrossBridge Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
CrossBridge Bio is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
CrossBridge Bio is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Seed of $10M, raised on Nov 2024.
CrossBridge Bio was founded in 2023 and is headquartered in Houston, United States. Antibody-Drug Conjugate therapeutics are developed within the biotechnology sector, with operations centered on a stable dual-linker payload technology. This technology supports various candidates, including the lead CB-120, which targets cancer treatment. Focus is placed on oncology applications through research and therapeutic development.
CrossBridge Bio offers ADC Technology Platform, EGCit Linker, and Enzymatic Conjugation.
CrossBridge Bio has 7 investors. Key investors include Lilly, TMC Venture Fund, CE Ventures, Crescent Enterprises, and Portal Innovations.
Yes. CrossBridge Bio was acquired by Lilly in April 2026.